At the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda, integration with the wider healthcare system was widely presented as a practical response to ...

“Lenacapavir is a product with real transformational potential that has the power to change the history of HIV,” Carolyn Amole of the Clinton Health Access Initiative (CHAI) told last week’s 13th ...

A man in southern California, dubbed the 'City of Hope patient', appears to be the latest person cured of HIV after receiving a stem cell transplant from a donor with a rare mutation, bringing the ...

Unanswered questions about the safety of taking PrEP during pregnancy and breastfeeding should not be allowed to stand in the way of access to PrEP for women who need it at these ...

Over half of funding for anti-gender actors in Europe appears to come from within Europe itself, with significant amounts of money also flowing from the US and the Russian Federation, according to ...

Once again, a life expectancy study has shown that HIV-positive people who start antiretroviral therapy (ART) promptly and have good access to medical care live as long as their HIV-negative peers.

Three-quarters of Australian gay and bisexual men who report unprotected anal intercourse with casual male partners say that they “often” or “always” employ some sort of risk reduction strategy with ...

A positive diagnosis continues to be a source of isolation and stigma for people living with HIV, especially among trans people, younger people and women. Findings from the UK’s largest survey of ...

Last year, a 66-year-old Californian woman, diagnosed with HIV in 1992, appeared in a local magazine as “The World’s First Known Person Who Naturally Beat HIV.” Loreen Willenberg had always been an ...

Despite the incredible efficacy of oral pre-exposure prophylaxis (PrEP) and 78 countries currently offering PrEP in some form, its effectiveness at reducing HIV incidence in the real world has been ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...

More than half of people who received a pair of broadly neutralising antibodies (bnAbs) plus the immune-modulating drug N-803 (Anktiva) had delayed viral rebound or maintained a low or suppressed ...